Trafficking of syngeneic murine lymphokine activated killer T cells following intraperitoneal administration in normal and tumor bearing mice.

[1]  H. Averette,et al.  Ovarian carcinoma.Advances in diagnosis, staging, and treatment , 1990, Cancer.

[2]  T. Whiteside,et al.  Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. , 1989, Cancer research.

[3]  G. Moore,et al.  Interleukin‐2—activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro , 1989, Cancer.

[4]  E. Fenig,et al.  Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function. , 1989, Journal of biological response modifiers.

[5]  W. Urba,et al.  Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. , 1989, Journal of the National Cancer Institute.

[6]  R. Albertini,et al.  Effect of commercial peritoneal dialysis fluids on the lytic function of lymphokine-activated killer cells. , 1988, Journal of biological response modifiers.

[7]  T. Nakamura,et al.  Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice. , 1988, Cancer research.

[8]  S. Jacques,et al.  Salvage immunotherapy of malignant glioma. , 1987, Archives of surgery.

[9]  K. Foon,et al.  Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. , 1987, Cancer research.

[10]  D. Longo,et al.  Biologic therapy for the treatment of malignant common epithelial tumors of the ovary , 1987, Cancer.

[11]  S. Jacques,et al.  Preliminary clinical trial of immunotherapy for malignant glioma. , 1987, Journal of biological response modifiers.

[12]  S. Rosenberg,et al.  Intraperitoneal administration of interleukin-2 in patients with cancer. , 1986, Archives of surgery.

[13]  P. Allavena,et al.  Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. , 1986, Journal of the National Cancer Institute.

[14]  C. Ware,et al.  The human LT system. XI. Identification of LT and "TNF-like" forms from stimulated natural killers, specific and nonspecific cytotoxic human T cells in vitro. , 1986, Journal of immunology.

[15]  L. Björck,et al.  Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. , 1985, Journal of immunology.

[16]  L. Björck,et al.  Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. , 1984, Journal of immunology.

[17]  Craig W. Reynolds,et al.  Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer. , 1984, Cellular immunology.

[18]  J. Talmadge,et al.  Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. , 1981, Cancer research.

[19]  B. B. Mishell,et al.  Selected Methods in Cellular Immunology , 1980 .

[20]  G. Granger,et al.  The LT system in experimental animals. II. Physical and immunologic characteristics of molecules with LT activity rapidly released by murine lymphoid cells activated on lectin-coated allogeneic monolayers in vitro. , 1979, Journal of immunology.

[21]  G. Granger,et al.  The LT system in experimental animals. I. Rapid release of high levels of lymphotoxin (LT) activity from murine lymphocytes during the interaction with lectin-treated allogeneic or xenogeneic target cells in vitro. , 1979, Journal of immunology.

[22]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[23]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[24]  P. Allavena,et al.  Lymphocytes infiltrating ovarian carcinoma: modulation of functional activity by intraperitoneal treatment with biological response modifiers. , 1988, Natural immunity and cell growth regulation.

[25]  Y. Nio,et al.  Immunologic control of ovarian cancer. , 1988, Natural immunity and cell growth regulation.

[26]  I. Bruderman,et al.  Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. , 1987, Cancer research.